Literature DB >> 8368127

Aging, comorbidity, and breast cancer survival: an epidemiologic view.

W A Satariano1.   

Abstract

This is a review of epidemiologic studies, which suggest that comorbidity (e.g., diabetes and heart disease) has an adverse effect on survival among women with incident, invasive breast cancer, adjusting for chronological age and stage of breast cancer at diagnosis. As part of this review, recent results are presented from a series of 463 breast cancer cases, identified through the Metropolitan Detroit Cancer Surveillance System. Women with two or more concurrent health conditions were 2.2 times more likely than breast cancer cases without comorbidity to die from their breast cancer over a four-year period (95% CI: 1.13, 4.18). Limiting heart disease was especially problematic. Recommendations are made for future research in this area.

Entities:  

Mesh:

Year:  1993        PMID: 8368127     DOI: 10.1007/978-1-4615-2926-2_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

Review 1.  Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making.

Authors:  Gretchen Kimmick
Journal:  Curr Treat Options Oncol       Date:  2011-09

2.  Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the Breast Cancer Family Registry.

Authors:  Theresa H M Keegan; Roger L Milne; Irene L Andrulis; Ellen T Chang; Meera Sangaramoorthy; Kelly-Anne Phillips; Graham G Giles; Pamela J Goodwin; Carmel Apicella; John L Hopper; Alice S Whittemore; Esther M John
Journal:  Breast Cancer Res Treat       Date:  2010-02-07       Impact factor: 4.872

3.  Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors.

Authors:  Thomas P Ahern; Timothy L Lash; Soe Soe Thwin; Rebecca A Silliman
Journal:  Med Care       Date:  2009-01       Impact factor: 2.983

Review 4.  Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients.

Authors:  Cesare Gridelli; Matti Aapro
Journal:  Support Care Cancer       Date:  2004-03-04       Impact factor: 3.603

5.  Position paper by the UKCCCR elderly cancer patients in clinical trials working group.

Authors: 
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.